Form 8-K - Current report:
SEC Accession No. 0001104659-25-004953
Filing Date
2025-01-21
Accepted
2025-01-21 17:25:13
Documents
13
Period of Report
2025-01-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm254046d1_8k.htm   iXBRL 8-K 26493
  Complete submission text file 0001104659-25-004953.txt   201289

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20250121_lab.xml EX-101.LAB 34240
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20250121_pre.xml EX-101.PRE 22373
4 XBRL TAXONOMY EXTENSION SCHEMA bcli-20250121.xsd EX-101.SCH 3036
15 EXTRACTED XBRL INSTANCE DOCUMENT tm254046d1_8k_htm.xml XML 3691
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 25543389
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)